• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 31, 2023 at 10:52: AM
via GSK (GSK.L) will pay about $1 billion for exclusive rights to further develop and commercialize Johnson & Johnson's (JNJ.N) hepatitis B therapy, the British drugmaker said on Tuesday.

JNJ-3989 was initially developed by Arrowhead Pharmaceuticals (ARWR.O) and licensed to Johnson & Johnson-owned Janssen in 2018.

article source
 




Top Bottom
Back
Quote